Results 91 to 100 of about 5,351 (123)

Successful Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infection with Sulbactam-Durlobactam: A Two-Case Report. [PDF]

Infect Drug Resist
Liu F, Wang DW.
europepmc   +1 more source

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol : which are the best present and future therapeutic alternatives ?

Purpose: To evaluate the different present and future therapeutic β-lactam/β-lactamase inhibitor (BL/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem ...
Le Terrier, Christophe, Freire, Samanta, Nordmann, Patrice, Poirel, Laurent   +3 more
core   +1 more source

Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review

Carbapenem-resistant Acinetobacter baumannii (CRAB) is characterized as a critical priority pathogen with restricted therapeutic options. To date, the most effective antimicrobial treatment against this difficult-to-treat bacterial strain has not been ...
Agouridis, Aris P, Alon-Ellenbogen, Danny, Mazonakis, Nikolaos, Ishak, Angela, Spernovasilis, Nikolaos, Tsioutis, Constantinos   +5 more
core   +1 more source

Sulbactam-Durlobactam for Carbapenem-resistant <i>Acinetobacter baumannii</i> in India: Does Local Molecular Epidemiology Support Current Guideline Recommendations? [PDF]

Indian J Crit Care Med
Mukkelli VG, Gupta R.
europepmc   +1 more source

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

, 2018
Chih-Cheng Lai,1 Chi-Chung Chen,2,3 Ying-Chen Lu,3 Yin-Ching Chuang,2,4 Hung-Jen Tang5,6 1Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan; 2Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan ...
Tang HJ, Lu YC, Chen CC, Lai CC, Chuang YC   +4 more
core  

New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]

Antimicrob Agents Chemother
Pogue JM, Harrington J, Wangchinda W, Kaye KS.   +3 more
europepmc   +1 more source

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]

J Antimicrob Chemother
Patterson-Fahy K, Carter R, Bell SC, Evans IES, Burke AJ, Thomson RM.   +5 more
europepmc   +1 more source

Critical Care Management of Pan-Resistant Acinetobacter Osteomyelitis Requiring Novel Antibiotic Therapy

A 65-year-old male with diabetes and chronic left heel osteomyelitis developed sepsis from pan-resistant Acinetobacter baumannii requiring emergent free flap surgery and initiation of sulbactam-durlobactam (Xacduro), a novel, rarely used antibiotic.
Navaratana, Nidhi, Soto, Roy, Thrasher, Patrick D, Shakibai, Nasim   +3 more
core   +1 more source

Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> with Diverse <i>β</i>-Lactamase Profiles: A Multicenter Study in China. [PDF]

Infect Drug Resist
Liu C, Chen Y, Wang L, Wang J, Xu D, Chen Z, Shu C, He Y.   +7 more
europepmc   +1 more source

Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i>: A Case Series and Literature Review. [PDF]

J Clin Med
Li R, Duan L, Sun S, Li D, Peng Q, Shang Y.   +5 more
europepmc   +1 more source